Objective To investigate the clinical efficacy of nimotuzumab combined with concurrent chemoradiother-apy in patients with locally advanced cervical cancer.Method A total of 72 patients with locally advanced cervical can-cer were divided into control group(n=30,received concurrent chemoradiotherapy)and observation group(n=42,re-ceived nimotuzumab combined with concurrent chemoradiotherapy)according to different treatment methods.The clini-cal efficacy,T lymphocyte subsets(CD4+,CD8+)levels,tumor markers[tumor specific growth factor(TSGF),carbohy-drate antigen 125(CA125),squamous cell carcinoma antigen(SCCA)]levels and the occurrence of adverse reactions were compared between the two groups.Result The total effective rate of the observation group was 90.48％,signifi-cantly higher than 63.33％of the control group(P＜0.01).After treatment,the levels of CD4+and CD8+in both groups were lower than those before treatment,and the levels of CD4+and CD8+in the observation group were higher than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the TSGF,CA125 and SCCA levels in both groups were lower than those before treatment,and the TSGF,CA125 and SCCA levels in the obser-vation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Ni-motuzumab combined with concurrent chemoradiotherapy in the treatment of local advanced cervical cancer patients can improve clinical efficacy and immune function,reduce the level of tumor markers,and have high safety.
维普
万方数据